Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

Texas Capital's Ratings Affirmed By Moody's, Outlook Stable

Published 02/25/2019, 10:17 PM
Updated 07/09/2023, 06:31 AM

Texas Capital Bancshares’ (NASDAQ:TCBI) ratings have been recently affirmed by Moody's Investors Service, the rating arm of Moody's Corporation (NYSE:MCO) . Moody's affirmed the company’s standalone baseline credit assessment (BCA) at baa2, while its long-term issuer rating is Baa3. The company’s ratings outlook remains stable.

Long- and short-term deposits of Texas Capital Bank, National Association — a subsidiary of Texas Capital Bancshares — are rated A3/Prime-2.

Factors Driving the Ratings

Texas Capital Bancshares’ healthy financial performance and strong asset quality are the key reasons behind the ratings affirmation. Also, Moody’s believes this upbeat trend to remain stable in the upcoming days despite higher credit losses and loan loss provisions.

The ratings also consider the company’s comparatively weak capitalization, deposit funding profile and good operating efficiency.

Low capitalization is a key credit challenge for Texas Capital Bancshares. Since the company is more focused on loan growth, it has low capital deployment activities which help it manage its capital position better. Moody’s anticipates Texas Capital Bancshares’ capitalization to improve in 2019 as it intends to grow the company’s loans at a higher rate than its peers. However, the rate of loan growth might be lower than the previous years.

Although Texas capital Bancshares’ strong asset quality reflects good underwriting standards and effective risk management, Moody’s considers its rapid loan growth and significant exposure toward commercial real estate to be risky. Hence, Moody’s considers the company’s decision to significantly lower its leveraged loan portfolio to be favorable. Also, its net charge-off ratio is lower than other rated U.S. banks.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Texas Capital Bancshares’ considerable deposit base results in its low reliance on confidence-sensitive market funding. Though the funding profile might weaken if the company loses a few important deposit relationships, it remains focused on improving deposit quality. Moody’s expect this improvement to take time and is not guaranteed.

Texas Capital Bancshares’ low cost structure supports its profitability. Since a significant portion of the company’s loan portfolio is exposed to floating rates related to short-term LIBOR, its profitability was further supported by higher interest rates.

Factors That Might Trigger Change in Ratings

An upward ratings change may occur if the company is able to significantly improve capitalization and increase its deposit granularity while maintaining underwriting standards and a good asset quality.

Meanwhile, downward rating pressure could emerge if Moody’s assess relaxation in the company’s internal control or underwriting in its loan portfolio. Ratings may also be downgraded if capitalization improvement does not materialize as projected by Moody’s.

Shares of the company have gained 5% over the past three months compared to industry’s rise of 5.2%.

Currently, the stock carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Key Picks

First Commonwealth Financial Corporation (NYSE:FCF) sports a Zacks Rank of 1, at present. Its shares have rallied 4.6% in the past three months.

Chemung Financial Corp (NASDAQ:CHMG) flaunts a Zacks Rank of 1, currently. Its shares have gained 11.6% in the past three months.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .


Moody's Corporation (MCO): Free Stock Analysis Report

First Commonwealth Financial Corporation (FCF): Free Stock Analysis Report

Texas Capital Bancshares, Inc. (TCBI): Free Stock Analysis Report

Chemung Financial Corp (CHMG): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.